Skip to main content

Table 1 Laboratory tests

From: Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report

 

Level measured

Reference range

《Biochemical Profiles》

 AST

131 U/L

(10–38)

 ALT

106 U/L

(5–40)

 γGTP

238 U/L

(0–75)

 ALP

439 U/L

(21–80)

 BUN

7.4 mg/dL

(8.0–21.0)

 Cr

0.53 mg/dL

(0.44–0.83)

 Na

145 mEq/L

(137–146)

 K

3.5 mEq/L

(3.5–4.9)

 Cl

111 mEq/L

(98–109)

 LDL-C

98 mg/dL

(70–139)

 HDL-C

38 mg/dL

(40–80)

 TG

106 mg/dL

(50–140)

 HbA1c

5.7%

(4.7–6.2)

 FPG

78 mg/dL

(60–109)

《Endocrine Profiles》

 GH

0.1 ng/mL

(<3.0)

 IGF-1

12 ng/mL

(83–221)

 PRL

13.3 ng/mL

(3.2–26.2)

 LH

<0.2 mIU/mL

(1.13–88.33)

 FSH

<0.1 mIU/mL

(3.01–16.60)

 E2

<7 pg/mL

(7–509)

 TSH

4.76 μU/mL

(0.50–3.00)

 FT4

0.6 ng/dL

(0.8–1.5)

 FT3

2.4 pg/mL

(2.1–3.8)

 ACTH

17.4 pg/mL

(7.2–63.3)

 cortisol

2 μg/dL

(2–18)

 u-cortisol

undetectable

(11.2–80.3)

 ADH

<0.8 pg/mL

(<4.2)

 s-Osm

289 mOsm/L

(270–295)

 u-Osm

250 L mOsm/L

(50–1300)

GHRP-2 loading test

 Time (min)

0

15

30

45

60

 GH (ng/mL)

0.1

0.4

0.4

0.3

0.2